IDEAS home Printed from https://ideas.repec.org/a/spr/hecrev/v15y2025i1d10.1186_s13561-025-00623-w.html
   My bibliography  Save this article

Cost-effectiveness analysis of duodenal–jejunal bypass sleeve device for people with obesity

Author

Listed:
  • Qian Xu

    (Fudan University
    Key Laboratory of Health Technology Assessment (Fudan University), National Health Commission)

  • Wei Yan

    (Fudan University
    Key Laboratory of Health Technology Assessment (Fudan University), National Health Commission)

  • Luo Li

    (Fudan University
    Key Laboratory of Health Technology Assessment (Fudan University), National Health Commission)

  • Bao Liu

    (Fudan University
    Key Laboratory of Health Technology Assessment (Fudan University), National Health Commission)

Abstract

Background Obesity has become major public health problem around the world. Lifestyle interventions, Pharmacotherapy and bariatric surgery are the common intervention to reduce weight in clinical practice. This study aims to conduct an economic evaluation of Duodenal–Jejunal Bypass Sleeve (DJBS) plus Intensive Lifestyle Intervention (ILI) compared with ILI only in people with obesity in China. Methods A hybrid model using a Decision Tree and Markov model was used to compare 9-month and lifetime horizon cost-effectiveness between DJBS plus ILI and ILI only. The data on clinical effectiveness were based on a prospective, open-label, and randomized trial (NCT05938231). This study employed 1–3 times the Gross Domestic Product (GDP) per capita (¥85,498, exchange rate: $1 US dollar = ¥6.73, 2022) and disposable income per capita (¥36,883, 2022) as the Willingness-To-Pay (WTP) thresholds. One-way, probabilistic sensitivity and scenario analysis were performed to test the robustness of the results. Results The results of the 9-month decision tree model showed that compared to ILI only, DJBS plus ILI decreased body mass index (BMI) by 1.69 kg/m2 (1.41 vs. 3.10), with an increasing cost of ¥28,963.98 yuan (¥29,111.06 vs.¥147.08). The incremental cost-effectiveness ratio (ICER) was ¥17,138.45 per unit decrease of BMI. The lifetime horizon model showed that compared to ILI only, DJBS plus ILI had a higher cost of ¥13261.94 yuan (¥31,688.98 vs. ¥18,427.04), while with a life-year increase of 0.02 (9.43 vs. 9.41) and quality-adjusted life years (QALYs) increase of 0.15 (7.82 vs. 7.67) per people with obesity. The ICER was ¥88,412.93 per QALY gained. Probability sensitivity analysis showed the robustness of the economic evaluation results. Conclusion The findings suggested that DJBS plus ILI was not a cost-effective strategy over a lifetime horizon when the WTP threshold was set at GDP per capita and disposable income per capita. However, it was considered cost-effective when the threshold was set at 1.03 times GDP per capita.

Suggested Citation

  • Qian Xu & Wei Yan & Luo Li & Bao Liu, 2025. "Cost-effectiveness analysis of duodenal–jejunal bypass sleeve device for people with obesity," Health Economics Review, Springer, vol. 15(1), pages 1-13, December.
    • Handle: RePEc:spr:hecrev:v:15:y:2025:i:1:d:10.1186_s13561-025-00623-w
    DOI: 10.1186/s13561-025-00623-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1186/s13561-025-00623-w
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1186/s13561-025-00623-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. David J. McLernon & John Dillon & Peter T. Donnan, 2008. "Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review," Medical Decision Making, , vol. 28(4), pages 582-592, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mohamed N.M.T. Al Khayat & Job F.H. Eijsink & Maarten J. Postma & Jan C. Wilschut & Marinus van Hulst, 2020. "The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands," IJERPH, MDPI, vol. 17(17), pages 1-13, August.
    2. Shan Liu & Michaël Schwarzinger & Fabrice Carrat & Jeremy D Goldhaber-Fiebert, 2011. "Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients," PLOS ONE, Public Library of Science, vol. 6(12), pages 1-14, December.
    3. Constanza L Vargas & Manuel A Espinoza & Andrés Giglio & Alejandro Soza, 2015. "Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile," PLOS ONE, Public Library of Science, vol. 10(11), pages 1-16, November.
    4. Job F. H. Eijsink & Mohamed N. M. T. Al Khayat & Cornelis Boersma & Peter G. J. Horst & Jan C. Wilschut & Maarten J. Postma, 2021. "Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 75-88, February.
    5. Mehdi Javanbakht & Jesse Fishman & Eoin Moloney & Peter Rydqvist & Amir Ansaripour, 2023. "Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis," PharmacoEconomics - Open, Springer, vol. 7(1), pages 93-110, January.
    6. Peasgood, T & Ward, S & Brazier, J, 2010. "A review and meta-analysis of health state utility values in breast cancer," MPRA Paper 29950, University Library of Munich, Germany.
    7. Louis Matza & Sandhya Sapra & John Dillon & Anupama Kalsekar & Evan Davies & Mary Devine & Jessica Jordan & Amanda Landrian & David Feeny, 2015. "Health state utilities associated with attributes of treatments for hepatitis C," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1005-1018, December.
    8. Hai Chen & Lijun Chen, 2017. "Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-15, April.
    9. Hla-Hla Thein & Yao Qiao & Ahmad Zaheen & Nathaniel Jembere & Gonzalo Sapisochin & Kelvin K W Chan & Eric M Yoshida & Craig C Earle, 2017. "Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-20, October.
    10. Shan Liu & Lauren E Cipriano & Mark Holodniy & Jeremy D Goldhaber-Fiebert, 2013. "Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-14, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:hecrev:v:15:y:2025:i:1:d:10.1186_s13561-025-00623-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/13561 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.